Ascendis Pharma A/S · below the panel floor
Ten analyst houses have published a target since Ascendis reported its second quarter on 13 August 2026, and all ten normalise to Buy. The lowest target in the panel, Morgan Stanley's 273 USD, now sits 3.6 per cent above the 11 September 2026 close of 263.52 USD, while the panel median implies a 22.4 per cent upside.
Snapshot as of 11 September 2026
All public targets
Ten houses have a dated target on record for Ascendis. All ten are included in the target aggregates, as they all published an update after Ascendis' second-quarter report of 13 August 2026.
Of the ten, three published in the days after the results, one opened coverage on 19 August, and six published after the BioMarin settlement of 31 August.
| House | Note | Target | DKK | Rec. | Last |
|---|---|---|---|---|---|
| H.C. Wainwright | [13] | 345 | 2,225 | Buy | 31 Aug |
| TD Cowen | [9] | 341 | 2,199 | Buy | 16 Aug |
| Jefferies | [14] | 330 | 2,128 | Buy | 31 Aug |
| Barclays | [10] | 329 | 2,121 | Overweight | 16 Aug |
| Stifel | [15] | 326 | 2,102 | Buy | 31 Aug |
| BMO Capital Markets | [12] | 319 | 2,057 | Outperform | 19 Aug |
| Oppenheimer | [17] | 312 | 2,012 | Outperform | 1 Sep |
| Bank of America | [16] | 304 | 1,960 | Buy | 31 Aug |
| RBC Capital | [11] | 290 | 1,870 | Outperform | 16 Aug |
| Morgan Stanley | [18] | 273 | 1,760 | Overweight | 1 Sep |
Buy in the Rec. column is the normalised rating. Three houses publish Outperform and two publish Overweight, and both labels normalise to Buy, which is why five rows show a rating the house itself does not use.
The DKK column is BioStock's own conversion at 6.4482 DKK per USD, derived from the European Central Bank reference rates of 11 September 2026. [7] No house published a target in DKK.
Coverage of the share is wider than the panel shown. Four covering houses are omitted because no current target could be matched to an individual dated notice, one house's most recent traceable note predates the window, and one maintains a rating without publishing a target.
Scroll the table sideways to see every column.
Where the panel sits
The share closed at 263.52 USD, below every target in the panel. The panel median of 322.5 USD sits 22.4 per cent above the current share price, and the panel distribution is weighted towards the lower half of its spread, from Morgan Stanley's 273 USD to H.C. Wainwright's 345 USD.
Buy · Hold · Sell
All ten houses in the window carry a Buy-equivalent rating after normalisation, and no house carries Hold or Sell.
Dated events behind the panel
- 30 Jun 2026ApproaCH week 104 shows continued lower-extremity alignment improvementTibial-femoral angle fell from 9.1 degrees at baseline to 6.9 degrees at week 104 across children treated with TransCon CNP, and from 13.4 to 9.6 degrees in those with pre-existing leg bowing. Growth-velocity gains reported earlier were sustained and no serious safety concerns were reported. [5]
- 6 Aug 2026COACH week 78 results and an update on YUVIWEL uptakeMean annualised growth velocity on the TransCon CNP and TransCon hGH combination reached the 97th percentile or above through week 78, at 7.73 cm per year in the treatment-naive cohort and 7.67 cm per year in the previously treated cohort, with all 21 enrolled children completing 78 weeks. The company reported more than 170 unique YUVIWEL patient enrolments through 30 June 2026, with reimbursement approved for over 65 per cent of them. [4]
- 13 Aug 2026Second-quarter revenue of 339 m EUR, up 115 per centTotal revenue reached 339 m EUR against 158 m EUR a year earlier, with YORVIPATH at 252 m EUR and SKYTROFA at 55 m EUR. The YUVIWEL marketing authorisation application remains under review at the European Medicines Agency with a decision anticipated in the fourth quarter of 2026. [1]
- 19 Aug 2026BMO Capital Markets initiates coverage at OutperformCoverage opened with a target of 319 USD, which sits close to the panel mean of 316.9 USD. [12]
- 31 Aug 2026Global settlement and licence agreement with BioMarin on YUVIWELAscendis takes a non-exclusive, worldwide, royalty-bearing licence, paying 20 per cent of net sales in the United States and 18 per cent in the European Union, South Korea and Brazil, running through 20 May 2030, and both parties dismiss all proceedings against each other. [2]
- 31 Aug – 1 Sep 2026Six houses publish in the two sessions after the settlementBank of America, Jefferies, Stifel and H.C. Wainwright published on 31 August, and Oppenheimer and Morgan Stanley on 1 September. Of the five that stated a previous target, one raised and four reduced. [13–18]
Four takeaways from the panel
Ascendis closed at 263.52 USD on 11 September 2026, below every target in the panel. The smallest gap is to Morgan Stanley's 273 USD, 3.6 per cent above the close, and the median of 322.5 USD implies 22.4 per cent. These targets reflect a second quarter with a 115 per cent rise in revenue and the BioMarin settlement that removed the litigation around YUVIWEL. [1][2][9–18]
Out of six houses that published reports after BioMarin's settlement, five had a previous target price: one raised it and four lowered it, and the net change across them was 1 USD lower. Even though a major uncertainty was resolved, the panel's view of the share stayed where it was. [13–18]
Every house rates Ascendis a Buy-equivalent with a pending regulatory ruling. The YUVIWEL marketing authorisation remains under review at the European Medicines Agency, with a decision anticipated in the fourth quarter of 2026. [1]
Morgan Stanley's 273 USD, the low of the panel, was published on 1 September 2026, after both the second-quarter report and the BioMarin settlement. It sits below the three houses that had only the second-quarter report to work from. [9–11][18]
Numbered sources
- Ascendis Pharma Reports Second Quarter 2026 Financial Results
- Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL (navepegritide)
- Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results
- Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs
- Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvement in Lower Extremity Alignment
- Ascendis Pharma Reports First Quarter 2026 Financial Results
- Euro foreign exchange reference rates, 11 September 2026
- Ascendis Pharma A/S Ordinary Share (ASND) historical data
- Ascendis Pharma price target raised to $341 from $325 at TD Cowen
- Ascendis Pharma price target lowered to $329 from $345 at Barclays
- Ascendis Pharma price target raised to $290 from $280 at RBC Capital
- BMO initiates Ascendis Pharma stock coverage with outperform rating
- H.C. Wainwright reiterates Ascendis Pharma stock rating at buy
- Jefferies lowers Ascendis Pharma stock price target on settlement
- Ascendis Pharma price target lowered to $326 from $328 at Stifel
- Ascendis Pharma price target lowered to $304 from $306 at BofA
- Oppenheimer raises Ascendis Pharma stock price target on settlement
- Ascendis Pharma price target lowered to $273 from $275 at Morgan Stanley
How the report was compiled
Selection. Consensus is compiled from publicly available target prices as of 11 September 2026. Each row cites the individual dated notice that published that house's latest revision. The window used for the aggregates opens either at the issuer's most recent interim report or 90 days before the snapshot. Here it opens at the second-quarter report of 13 August 2026, and all ten houses fall inside it, so no target is badged or excluded. A house whose latest target could not be matched to a dated notice is omitted rather than carried on an unverified figure, so coverage of the share is wider than the ten houses shown. Providers of independent research sold to end investors are outside the panel.
Price and valuation basis. The reference price is 263.52 USD, the closing price on Nasdaq on 11 September 2026. [8] Market capitalisation is computed on 65,673,284 shares outstanding, being the 66,189,926 ordinary shares outstanding at 30 June 2026 less the 516,642 shares held in treasury at that date. [1] The price-earnings ratio is computed on trailing twelve months: the 2025 full-year diluted loss per share of 3.76 EUR, less the first-half 2025 diluted loss per share of 2.22 EUR as printed in the comparative column of the current interim report, plus first-half 2026 diluted earnings of 12.73 EUR, giving 11.19 EUR. [1][3] That denominator is dominated by the recognition of previously unrecognised deferred tax assets of 679 m EUR in the first quarter of 2026, so the multiple should not be read as a measure of operating earnings. [6] Earnings are reported in euro and the share trades in US dollars; the conversion uses 1.1592 USD per euro (European Central Bank reference rates, 11 September 2026). Targets are shown as published, in USD, with a DKK column converted by BioStock at 6.4482 DKK per USD, from the same source's rates. Where this report states what a house carried before a revision, that figure comes from the notice that superseded it.
Ratings. Buy, Overweight, Outperform and Accumulate are counted as Buy. Hold, Neutral and Market Perform are counted as Hold. Sell, Underweight, Reduce and Underperform are counted as Sell. The panel table shows the normalised rating and the note below it names the houses whose own label differs.
Take this analysis with you
A ten-house panel with a ten-house consensus, ready to share or print.
Download PDF